back to US directory
us clinical guidance

Migraine acute treatment and prevention

US individualized acute and preventive migraine care, medication-overuse control, reproductive safety and escalation.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adolescents and adults with a clinically established episodic or chronic migraine phenotype. This page does not cover status migrainosus infusion protocols, hemiplegic or retinal migraine, pregnancy-specific prescribing, pediatric dosing or cluster headache. Product choice requires current FDA labeling, contraindications and insurance criteria in addition to the 2023 VA/DoD evidence review.
sources for this section:VA/DoD headache 2023

The Bottom Line

  • Treat attacks early with an individualized plan that considers severity, nausea, route, previous response, cardiovascular disease, pregnancy and interactions rather than cycling randomly through rescue products.
  • VA/DoD supports selected triptans and nonopioid analgesics for acute migraine and suggests oral gepants for appropriate patients; choose within current FDA labeling and patient-specific safety constraints.
  • Offer prevention when attack frequency, disability, prolonged attacks, medication overuse or patient preference justifies it, and select among source-supported oral, injectable and behavioral options through shared decision-making.
  • Set a measurable target using monthly migraine days, acute-medication days and function, allow an adequate trial at a tolerated dose and reassess benefit before continuing indefinitely.
sources for this section:VA/DoD headache 2023

Practical clinical workflow

1
Confirm migraine features and aura, record baseline frequency and disability, identify nausea or allodynia, review cardiovascular and pregnancy risk, and reconcile every acute medicine including caffeine combinations.
2
Build a stepped home rescue plan with a primary agent, route, timing, repeat or backup instructions and a limit on medication days; address hydration, sleep and predictable triggers pragmatically.
3
Discuss prevention options by evidence, comorbidity, weight, blood pressure, mood, reproductive plans, adherence, cost and route; titrate one change at a time when feasible.
4
Review diary outcomes and adverse effects after an appropriate interval, taper ineffective preventive therapy safely and escalate refractory chronic migraine or diagnostic uncertainty to headache expertise.
sources for this section:VA/DoD headache 2023

Safety boundaries and escalation

  • A first aura with motor weakness, persistent deficit, abrupt maximal-onset pain or a materially different attack requires evaluation for stroke, hemorrhage or another secondary cause.
  • Check vasoconstrictor contraindications and interactions before triptans or ergot derivatives; do not infer that a newer drug is safe in pregnancy or vascular disease without current labeling.
  • Frequent use of triptans, combination analgesics, opioids or simple analgesics can sustain medication-overuse headache; prevention and a structured withdrawal plan may be necessary.
  • Suicidal thinking, severe depression, uncontrolled hypertension, pregnancy planning or serious treatment adverse effects should change the preventive choice and follow-up intensity.
sources for this section:VA/DoD headache 2023

Localization

US preventive access is strongly shaped by FDA indications and payer step requirements, which are not clinical evidence thresholds. The 2023 VA/DoD guideline predates some subsequent label expansions, so every prescribed product needs a live label check.
sources for this section:VA/DoD headache 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Department of Veterans Affairs and U.S. Department of Defense Evidence-Based Practice Work GroupVA/DoD Clinical Practice Guideline for Management of Headache2023 guideline; official page updated 2025-07-11 路 published 2023-09-01 路 updated 2025-07-11 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.